Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients ; volume:4 ; number:1 ; day:16 ; month:8 ; year:2006 ; pages:1-11 ; date:6.2006
Journal of translational medicine ; 4, Heft 1 (16.8.2006), 1-11, 6.2006
- Creator
-
Ridolfi, Ruggero
- Contributor
-
Petrini, Massimiliano
Fiammenghi, Laura
Stefanelli, Monica
Ridolfi, Laura
Ballardini, Michela
Migliori, Giuseppe
Riccobon, Angela
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-4-36
- URN
-
urn:nbn:de:1111-2016041431213
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ridolfi, Ruggero
- Petrini, Massimiliano
- Fiammenghi, Laura
- Stefanelli, Monica
- Ridolfi, Laura
- Ballardini, Michela
- Migliori, Giuseppe
- Riccobon, Angela
- SpringerLink (Online service)
Other Objects (12)
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML
Mechanism of dendritic cell-based vaccination against Leishmania major
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML
Mechanism of dendritic cell-based vaccination against Leishmania major
Improved dendritic cell vaccination for combined melanoma immune therapy
Improved dendritic cell vaccination for combined melanoma immune therapy
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
Current status of dendritic cell-based tumor vaccination
S43. Dendritic cell vaccination combined with CTLA4 blockade
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
T-Cell stimulation by melanoma RNA-pulsed dendritic cells
Phase I/II study of vaccination with immature and mature dendritic cells in patients with melanoma and renal cell carcinoma
P55. Dendritic cell vaccination for postremission therapy in AML